Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630672 | 1.00 | NFE2L2 (0.53) | NFE2L2RELAKDM4ENPC1ALDH1A1 | |
| SCHEMBL5785998 | 0.85 | CHAT (0.47) | RELAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5785995 | 0.85 | CHAT (0.47) | RELAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9323561 | 0.83 | LMNA (0.50) | RELAKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL9323556 | 0.83 | LMNA (0.50) | RELAKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL5791786 | 0.82 | NFE2L2 (0.53) | NFE2L2RELAKDM4ENPC1ALDH1A1 | |
| SCHEMBL5791782 | 0.82 | NFE2L2 (0.53) | NFE2L2RELAKDM4ENPC1ALDH1A1 | |
| SCHEMBL5787784 | 0.81 | NFE2L2 (0.51) | NFE2L2RAB9AFLT3 | |
| SCHEMBL5787790 | 0.81 | NFE2L2 (0.51) | NFE2L2RAB9AFLT3 | |
| SCHEMBL5790627 | 0.80 | RELA (0.53) | NFE2L2RELANPC1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| CN-101528710-B | Aminomethyl-4-imidazoles | HOFFMANN LA ROCHE | 2012-11-07 | — | — | CN | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| CN-101528710-A | Aminomethyl-4-imidazoles | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | CN | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| EP-1335906-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| CN-1473156-A | Pyrimidine derivatives and their use as neuropeptide y receptor ligands | - | 2004-02-04 | — | — | CN | disclosed |
| US-6657060-B2 | Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia | HOFFMAN-LA ROCHE INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1335906-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2003-08-20 | — | — | EP | disclosed |
| US-20020086858-A1 | Pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | US | disclosed |
| WO-2002038551-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | NFE2L2 946/4885RELA 2343/4885KDM4E 69/4885 |
| US-20020086858-A1 | Pyrimidine derivatives | NPY1R, NPY5R, NPY4R | NFE2L2 3894/4885RELA 2644/4885KDM4E 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.